Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

James Thompson, Lisa Rein, Michael Mauro, Srinivas Tantravahi, Jay Yang, Arielle Baim, Sonia Maldonado-Schmidt, Claire Olig, Kathryn Flynn, Yan Gao, Jerald Radich, Ehab Atallah, Jorge Cortes

Blood (2025) 146 (Supplement 1): 7311.

https://doi.org/10.1182/blood-2025-7311

Published: 2025

Journal Articles

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

Ehab Atallah, Emily Giever, Jorge Cortes, Ryan Conrardy, Lisa Rein, Arielle Baim, Idayat Akinola, James Thompson, Yan Gao, Richard Larson, Ravi Bhatia, B. Douglas Smith, Kathryn Flynn

Blood (2025) 146 (Supplement 1): 2844.

https://doi.org/10.1182/blood-2025-2844

Published: 2025

Journal Articles

Machine learning accurately predicts mortality in adult NPM1-mutant Acute Myeloid Leukemia using baseline clinical and genomic features

Rahul Thakur, Sophie Thieme, Marcus Dempster, Nikhil Chaudhary, Sandhya Mishra, Tara Cronin, Steven Green, James Thompson, Elizabeth Griffiths, Pamela Sung, Eunice Wang

Blood (2025) 146 (Supplement 1): 6116.

https://doi.org/10.1182/blood-2025-6116

Published: 2025

Journal Articles

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Donald E. Tsai, MD, PhD, Selina Luger, MD, Allison Kemner, RN, Alison W. Loren, MD, Cezary Swider, PhD, Ami Goradia, MD, Charalambos Andreadis, MD, Richard G. Ghalie, MD, James Thompson, MD, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Alexander Perl, MD, Adam Bagg, MD, Steven Goldstein, MD, Martin Carroll, MD

Blood (2006) 108 (11): 1955.

https://doi.org/10.1182/blood.V108.11.1955.1955

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

Machine learning accurately predicts mortality in adult NPM1-mutant Acute Myeloid Leukemia using baseline clinical and genomic features

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Email alerts

ASH Publications

American Society of Hematology

Update search

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

Machine learning accurately predicts mortality in adult NPM1-mutant Acute Myeloid Leukemia using baseline clinical and genomic features

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only